Olaparib

Extended indication	Extension of indication for Lynparza in combination with Imfinzi for the maintenance treatment of adult patients with newly diagnosed advanced or recurrent endometrial cancer following treatment with Imfinzi and platinum-based chemotherapy.
Therapeutic value	No estimate possible yet
Registration phase	Registration application pending

Product

Active substance	Olaparib
Domain	Oncology
Reason of inclusion	Indication extension
Extended indication	Extension of indication for Lynparza in combination with Imfinzi for the maintenance treatment of adult patients with newly diagnosed advanced or recurrent endometrial cancer following treatment with Imfinzi and platinum-based chemotherapy.
Proprietary name	Lynparza
Manufacturer	AstraZeneca

Registration route	Centralised (EMA)
Type of trajectory	Normal trajectory
Submission date	October 2023
Expected Registration	August 2024
Registration phase	Registration application pending

Therapeutic value	No estimate possible yet
References	NCT04269200

There is currently nothing known about the expected patient volume.

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.